NCT00718601View on ClinicalTrials.gov

Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Multiple Myeloma
Interventions
DRUG

Imetelstat Sodium (GRN163L)

25% dose escalation infused over 2 hours weekly

Trial Locations (3)

10011

St. Vincent's Comprehensive Cancer Center, New York

48201

Karmanos Cancer Center, Detroit

98109

Fred Hutchinson Cancer Research Center, Seattle

Sponsors

Lead Sponsor

Geron Corporation
All Listed Sponsors
lead

Geron Corporation

INDUSTRY